Nov 02, 2016 12:01 pm UTC| Business
Pilot Study Designed to Enable Progression to Larger Phase 2 Trial to Finalize Dosing and Endpoints Prior to Single Pivotal Study Trial Will Assess 12-week Safety and Tolerability in Outpatient Setting; Topline Data...
CymaBay to Announce Third Quarter 2016 Financial Results on Wednesday, November 9
Nov 02, 2016 12:01 pm UTC| Business
NEWARK, Calif., Nov. 02, 2016 -- CymaBay Therapeutics, Inc. (NASDAQ:CBAY), a clinical-stage biopharmaceutical company focused on developing therapies to treat metabolic diseases with high unmet medical need, today...
CymaBay to Announce Third Quarter 2016 Financial Results on Wednesday, November 9
Nov 02, 2016 12:01 pm UTC| Business
NEWARK, Calif., Nov. 02, 2016 -- CymaBay Therapeutics, Inc. (NASDAQ:CBAY), a clinical-stage biopharmaceutical company focused on developing therapies to treat metabolic diseases with high unmet medical need, today...
Calithera Biosciences to Report Third Quarter 2016 Financial Results on Wednesday, November 9, 2016
Nov 02, 2016 12:01 pm UTC| Business
SOUTH SAN FRANCISCO, Calif., Nov. 02, 2016 -- Calithera Biosciences, Inc. (Nasdaq:CALA), a clinical-stage pharmaceutical company focused on discovering and developing novel small molecule drugs directed against tumor...
Calithera Biosciences to Report Third Quarter 2016 Financial Results on Wednesday, November 9, 2016
Nov 02, 2016 12:01 pm UTC| Business
SOUTH SAN FRANCISCO, Calif., Nov. 02, 2016 -- Calithera Biosciences, Inc. (Nasdaq:CALA), a clinical-stage pharmaceutical company focused on discovering and developing novel small molecule drugs directed against tumor...
Nov 02, 2016 12:01 pm UTC| Business
SEATTLE and SOUTH SAN FRANCISCO, Calif., Nov. 02, 2016 -- Immune Design (Nasdaq:IMDZ), a clinical-stage immunotherapy company focused on cancer, today announced that it will report third quarter 2016 financial results...
Nov 02, 2016 12:01 pm UTC| Business
SEATTLE and SOUTH SAN FRANCISCO, Calif., Nov. 02, 2016 -- Immune Design (Nasdaq:IMDZ), a clinical-stage immunotherapy company focused on cancer, today announced that it will report third quarter 2016 financial results...